Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Consumers are clear in this new survey that they do not want to consume cow’s milk affected by bird flu virus, even if the ...

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

There are currently three approved vaccines against the H5N1 avian influenza virus. However, they present challenges for large-scale virus cultivation in case of an outbreak and rapid update of ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

SAN DIEGO, January 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

The material developed by NIST includes three segments of RNA corresponding to certain proteins of the H5N1 virus—the hemagglutinin, neuraminidase and matrix proteins. Most H5N1 tests rely on the ...

Recent history makes clear that microbiological disasters can strike anytime. But a longer history should remind us of the ...